Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Oral Lixivaptan Capsules in Subject With Euvolemic Hyponatremia

This study has been completed.
Cardiokine Biopharma, LLC
Information provided by:
CardioKine Inc. Identifier:
First received: April 15, 2008
Last updated: June 20, 2011
Last verified: November 2010
The present study is designed to confirm and extend the observation from previous studies that lixivaptan therapy corrects hyponatremia, in euvolemic subject, including subjects with SIADH.

Condition Intervention Phase
Hyponatremia With Normal Extracellular Fluid Volume
Drug: lixivaptan
Drug: placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Lixivaptan Capsules in Subject With Euvolemic Hyponatremia

Further study details as provided by CardioKine Inc.:

Primary Outcome Measures:
  • Average daily area under the curve (AUC) of change from baseline in serum sodium concentrations up to 72 hrs in lixivaptan treated subjects compared to placebo [ Time Frame: 60 days ]

Secondary Outcome Measures:
  • Change from baseline in serum sodium on Day 30 [ Time Frame: 60 days ]
  • Percentage of subjects achieving normalized serum sodium (Na+ ≥ 135 mEq/L) [ Time Frame: 60 days ]
  • Time to first normalization of serum sodium (Na+≥135 mEq/L) [ Time Frame: 60 days ]

Enrollment: 106
Study Start Date: April 2008
Primary Completion Date: June 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Active Comparator
Drug: lixivaptan
oral capsule
Placebo Comparator: Placebo
Drug: placebo
oral capsule

Detailed Description:
Phase I Phase II clinical trials have demonstrated that lixivaptan may play an important role in treating hyponatremia and the signs and symptoms of water retention associated with HF, liver cirrhosis with ascites (LCWA) and syndrome of inappropriate antidiuretic hormone (SIADH). Lixivaptan was previously evaluated in disease states characterized by hyponatremia with euvolemia (SIADH)and hyponatremia combined with fluid overload (HF, LCWA). Lixivaptan resulted in correction in hyponatremia together with a marked aquaresis in subject with volume overload. The present study is designed to confirm and extend the observation from previous studies that lixivaptan therapy corrects hyponatremia, in euvolemic subject, including subjects with SIDH.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Written informed consent
  • Men or women aged 18 or older
  • Diagnosis of euvolemic hyponatremia (120 ≤ Na+<130 mEq/L)
  • Hospitalized or willing to be admitted to a monitored setting for approximately the first 48 hours of treatment

Exclusion Criteria:

  • Pregnant or breast-feeding women, or women planning to become pregnant or to breastfeed
  • Symptomatic hyponatremia (e.g., lethargy, coma, seizures, changes in mental status attributable to hyponatremia)
  • Acute or transient hyponatremia (e.g., associated with head trauma or postoperative state)
  • Hyponatremia in hypovolemic states. Hypovolemic hyponatremia is defined as the presence of clinical evidence of extracellular fluid volume depletion
  • Hyponatremia as a result of any medication that can safely be withdrawn
  • Hyponatremia due to hypothyroidism or adrenal insufficiency
  • Diagnosis of psychogenic polydipsia
  • Receiving within 7 days of enrollment, other medication for treatment of hyponatremia specifically: demeclocycline, lithium carbonate, urea, or conivaptan
  • Use of radiotherapy and chemotherapy within 2 wks of randomization
  • Likely to require, or to receive IV saline for correction of symptomatic or asymptomatic severe hyponatremia during the course of the study
  • Supine systolic arterial blood pressure of ≤ 90 mmHg
  • Serum creatinine >3.0 mg/dL
  • History of uncontrolled type 2 diabetes mellitus
  • Severe pulmonary artery hypertension: patients whose condition is expected to deteriorate with sudden shifts in fluid volumes and cardiac filling pressures
  • Established diagnosis of New York Heart Association (NYHA) class III or IV heart failure
  • History of myocardial infarction, unstable angina or evidence of active ischemia within 30 days prior to screening
  • History of cerebral vascular accident (CVA) within 60 days prior to screening
  • Established diagnosis of nephrotic syndrome
  • Advanced liver disease or documented diagnosis of cirrhosis or alcoholic hepatitis
  • Urinary tract obstruction (benign prostatic hypertrophy [BPH] allowed if non-obstructive)
  • History of alcohol abuse or illicit drug use within the past 6 months
  • Terminally ill or moribund condition with little chance of short-term survival
  • Receiving vasopressin or its analogs for treatment of any condition
  • Known allergy to any vasopressin antagonist
  • Previous participation in a lixivaptan study
  • Recipient of any investigational treatment (drug or device) within 30 days prior to baseline visit
  • Unable to take oral medications
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00660959

  Show 71 Study Locations
Sponsors and Collaborators
CardioKine Inc.
Cardiokine Biopharma, LLC
  More Information

Responsible Party: Cardiokine, Inc Identifier: NCT00660959     History of Changes
Other Study ID Numbers: CK-LX3405
Study First Received: April 15, 2008
Last Updated: June 20, 2011

Keywords provided by CardioKine Inc.:
Serum Sodium
Fluid Overload
Vasopressin Antagonist

Additional relevant MeSH terms:
Water-Electrolyte Imbalance
Metabolic Diseases processed this record on May 25, 2017